TITLE

The use of compound topical anesthetics

AUTHOR(S)
Kravitz, Neal D.
PUB. DATE
October 2007
SOURCE
Journal of the American Dental Association (JADA);Oct2007, Vol. 138 Issue 10, p1333
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a research which examines U.S. federal regulations regarding the risks and adverse effects of five compound topical anesthetics. The research found that compound topical anesthetics are neither regulated nor unregulated by the Food and Druh Administration (FDA). Some compounding pharmacies bypass the FDA drug approval process. The FDA has strengthened its efforts against unapproved drug products.
ACCESSION #
27254769

 

Related Articles

  • Warning Regarding Topical Anesthetics.  // Internal Medicine Alert;3/15/2009 Pharmacology Watch, p1 

    The article offers updates related to pharmacology in the U.S. The U.S. Department of Food and Drug Administration warned the public about the life-threatening side effects of topical anesthetics. Both atypical and typical antipsychotic medications can increase the incidence of sudden cardiac...

  • FDA Actions. Elliott, William T. // Clinical Cardiology Alert;Mar2007 Pharmacology Watch, p2 

    The article reports on a warning issued by the U.S. Food and Drug Administration (FDA) on the unsupervised use of topical anesthetic products for cosmetic procedures. FDA received several complaints on the adverse effects of topical agents containing lidocaine, tetracaine, benzocaine and...

  • FDA Actions. Elliott, William T. // Clinical Oncology Alert;Mar2007 Pharmacology Watch, p2 

    The article reports on a warning issued by the U.S. Food and Drug Administration (FDA) on the unsupervised use of topical anesthetic products for cosmetic procedures. FDA received several complaints on the adverse effects of topical agents containing lidocaine, tetracaine, benzocaine and...

  • Drug Safety: Most Drugs Withdrawn in Recent Years Had Greater Health Risks for Women: GAO-01-286R.  // GAO Reports;1/19/2001, p1 

    The Food and Drug Administration (FDA) approves drugs for sale in the United States when it determines that the clinical benefits of a drug outweigh its potential health risks. To make this decision, FDA reviews supporting data collected from several thousand patients during the drug's...

  • Prescribing more intelligently. Singer, Karl // Patient Care;10/15/1999, Vol. 33 Issue 16, p9 

    Relates the dilemma faced by the United States Food and Drug Administration in approving drugs for a previously untreatable illness. Release of tacrine for Alzheimer's disease; Side effects of an antiplatelet agent called ticlopidine; Need for physicians in the US to participate in...

  • FDA Issues Regulation Prohibiting Sale of Dietary Supplements Containing Ephedra. Ressel, Genevieve // American Family Physician;3/15/2004, Vol. 69 Issue 6, p1343 

    Reports that the U.S. Food and Drug Administration has issued a final rule that prohibited the sale of dietary supplements containing ephedra. Side effects of ephedra.

  • FDA warns against domperidone use during lactation.  // Drug Topics;6/21/2004, Vol. 148 Issue 12, p16 

    This article reports on the issuance of an advisory by the U.S. Food and Drug Administration for women not to use the drug domperidone while breast-feeding. The drug is used by women to increase lactation and that this may put them at risk for serious cardiac problems and sudden death.

  • FDA Actions. Elliott, William T. // Primary Care Reports;Jul2009 Pharmacology Watch, p2 

    The article reports on U.S. drug policy. The U.S. Food and Drug Administration (FDA) requires two brands of testosterone gel to carry boxed warnings after receiving reports that the gel might cause enlarged genitalia, premature development of pubic hair, and advanced bone age in children. The...

  • FDA Actions. Elliott, William T. // Clinical Oncology Alert;Feb2008 Pharmacology Watch, Vol. 24, p2 

    The article reports on the regulatory actions taken by the U.S. Food and Drug Administration (FDA) regarding various drugs as of February 2008. An FDA advisory panel recommended the disapproval of Merck's petition for over-the-counter (OTC) status for the cholesterol-lowering drug, lovastatin....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics